Background: Overexpression of connective tissue growth factor (CTGF) in alveolar type II epithelial (AT II) cells disrupts alveolar structure, causes interstitial fibrosis, and upregulates integrin-linked kinase (ILK). Whether CTGF-ILK signaling induces epithelial to mesenchymal transition (EMT) in AT II cells is unknown. Methods: Transgenic mice with targeted overexpression of CTGF in AT II cells were generated utilizing the surfactant protein C (SP-C) gene promoter and doxycycline-inducible system. AT II cells were isolated from 4-wk-old CTGF-overexpressing (CTGF+) mice and control littermates, and cultured on Matrigel. Cells were transfected with ILK siRNA, and cell morphology and expression of cell differentiation markers were analyzed. results: The AT II cells from the control lungs grew in clusters and formed alveolar-like cysts and expressed SP-C. In contrast, the cells from CTGF+ lungs were spread and failed to form alveolar-like cysts. These cells expressed higher levels of CTGF, α smooth muscle actin (α-SMA), fibronectin and vimentin, the mesenchymal markers, suggesting EMT-like changes. Transfection with ILK siRNA not only dramatically attenuated ILK expression, but also decreased α-SMA expression as well as reversed cell morphological changes in CTGF+ AT II cells. conclusion: Overexpression of CTGF induces EMT in mouse primary AT II cells and this is mediated by ILK.
INTRODUCTION
Pulmonary fibrosis occurs in a variety of clinical sittings and affects patients of all ages. Interstitial lung fibrosis is one of pathological hallmarks of bronchopulmonary dysplasia, also known as chronic lung disease of premature infants (1) . Idiopathic pulmonary fibrosis is the most common and severe form of interstitial lung disorder in adult patients (2) . Pulmonary fibrosis causes destruction of alveolar structure and respiratory function, and progressive fibrosis is a significant cause of morbidity and mortality and there is no effective therapy. Although the histopathologic pattern of lung fibrosis has been long recognized to consist of nonspecific interstitial fibrosis, resulting from fibroblast proliferation, myofibroblast differentiation and excessive deposition of extracellular matrix (ECM), the specific molecular and cellular mechanisms are unknown (2) .
The key effector cell in fibrogenesis is the myofibroblast which is responsible for the synthesis and deposition of ECM and the resultant structural remodeling that leads to the loss of alveolar structure and end-stage lung disease (3) . These myofibroblasts have been traditionally thought to be differentiated directly from resident alveolar fibroblasts under the influence of the profibrotic microenvironment (2, 3) . However, novel concepts of fibrogenesis indicate a role of epithelialmesenchymal transition (EMT) as a source of myofibroblasts following epithelial injury (4, 5) . A number of growth factors have been implicated in the pathogenesis of lung fibrosis, and transforming growth factor β (TGF-β) is one of the most critical factors implicated (6) (7) (8) . TGF-β has the ability to stimulate both fibroblast to myofibroblast differentiation and EMT. Indeed, strategies to block the biological activity of TGF-β, including neutralizing antibodies, soluble receptors, and pharmacological inhibitors of Smad proteins, have been used in animal models with varying degrees of attenuation of lung fibrosis (6, (9) (10) (11) . However, given the exceptionally broad range of biological activity ascribed to TGF-β and its fundamental physiological roles, nonselective TGF-β blockade could have undesired consequences. Complete abrogation of TGF-β signaling could lead to loss of immune tolerance, spontaneous autoimmunity and defective tissue repair (12) . Therefore, identification of novel mediators and mechanisms will not only enhance our understanding of the pathogenesis of lung fibrosis but also provide effective targets for treating this devastating disease.
Connective tissue growth factor (CTGF), a multimodular matrix-associated protein, is thought to be the downstream mediator of TGF-β with a particular role in stimulating fibroblast proliferation, fibroblast to myofibroblast differentiation and ECM deposition (13) (14) (15) . Expression of CTGF is upregulated by TGF-β and anti-CTGF antibody blocks TGF-β-induced fibrogenic effects (16) (17) (18) . Upon stimulation, CTGF is secreted into the extracellular environment where it interacts with distinct cell surface receptors, growth factors and ECM. The principal CTGF receptor is the heterodimeric cell surface integrin complexes (19) (20) (21) , while integrin-linked kinase (ILK) is a key mediator of integrin signaling that interacts with the cytoplasmic domain of β integrins (22) (23) (24) . Most Articles importantly, ILK signaling plays a critical role in EMT under many pathological conditions (25) (26) (27) .
There is increasing evidence that CTGF plays an important role in lung fibrosis. Increased CTGF expression is detected in patients with lung fibrosis and bronchopulmonary dysplasia (28) (29) (30) . Transgenic overexpression of CTGF in fibroblasts resulted in systemic fibrosis, including the lung (31) . Furthermore, in vivo and in vitro studies have shown that expression of CTGF in lung epithelial cells or treatment with exogenous CTGF induces EMT-like changes (32) . Previous studies from our laboratory have demonstrated that targeted overexpression of CTGF in alveolar type II epithelial (AT II) cells disrupts alveolar structure and induces interstitial fibrosis, and these pathological changes were associated with activation of ILK signaling (33) . It is known that ILK mediates CTGF-induced EMT in renal tubular cells (34) . However, whether ILK mediates CTGFinduced EMT in AT II cells is unknown.
To test the hypothesis that overexpression of CTGF in AT II cells induces EMT and this is mediated by ILK, we cultured primary AT II cells that were isolated from transgenic mice with targeted overexpression of CTGF in these cells and performed transfection with ILK siRNA. We demonstrated that AT II cells with overexpression of CTGF undergo EMT-like changes and knockdown of ILK gene attenuates this process.
RESULTS

Overexpression of CTGF Induces EMT-Like Phenotype in AT II Cells
After being cultured for 96 h, the control cells grew in clusters and formed alveolar-like cysts (Figure 1a) . In contrast, the 
. We also assessed expression of additional two mesenchymal markers, vimentin and fibronectin, and found that ILK siRNA significantly decreased their gene expression in CTGF+ cells to the levels in control cells (Figure 6 ). These data suggest that ILK mediates CTGF-induced EMT in AT II cells.
DISCUSSION
In this study, we demonstrate that primary AT II cells from mice with targeted overexpression of CTGF under the control of SP-C gene promoter undergo EMT-like changes in culture and these were associated with upregulation of ILK. Most importantly, we showed the evidence that ILK mediates CTGF-induced EMT-like phenotype in AT II cells. These data highlight a novel autocrine mechanism by which CTGF-ILK signaling regulates EMT in AT II cells. CTGF is a multimodular matrix-associated protein that plays an important role in cell proliferation, differentiation, cell survival, and ECM production during tissue development and injury repair. Recent advances in genetic modification technology have provided us with the ability to highlight the cell-specific role of CTGF in lung development and pathology. Ivkovic et al. (35) have shown that global knockout of CTGF results in respiratory failure and immediate death in newborn mice suggesting that endogenous CTGF in lung cells are important for embryonic lung development and newborn lung function. Sonnylal et al. (31, 32) demonstrated that targeted overexpression of CTGF in lung fibroblasts induces fibrosis which affects both lung fibroblasts and epithelial cells indicating that fibroblast-derived CTGF results in lung fibrosis via both autocrine Articles Shafieian et al.
and paracrine mechanisms. Our previous studies showed that targeted overexpression of CTGF in AT II cells disrupts alveolar development and induces lung fibrosis (33) . Our unpublished data also showed that there are increased CTGF concentrations in bronchoalveolar lavage fluid and serum in mice with overexpression of CTGF in AT II cells. Taken together, these results suggest that both epithelial and mesenchymal CTGF are critical for lung development and lung fibrosis. It is suggested that repeated injury to the alveolar epithelium sets up a cascade of dysregulated epithelial-mesenchymal crosstalk, through the release of growth factors, matrix metalloproteinase, cytokines, and chemokines that in turn leads to mesenchymal cell activation/proliferation and fibrogenesis (36, 37) . However, increasing evidence indicates that alveolar epithelial cells have the ability to undergo EMT upon injury and exposure to certain stimuli, and this contributes to pulmonary fibrosis (4, 5) . During EMT, epithelial cells loss apicalbasal polarity, basement membrane attachment and cell-cell contact, and gain mesenchymal cell features and behavior. Many growth factors and signaling molecules have been implicated in this process, and TGF-β is one of the critical factors that have been extensively studied (38, 39) . Although CTGF is a downstream mediator of many of TGF-β fibrogenic actions, the role of CTGF in EMT, particular in AT II cell EMT is poorly understood.
In this study, we isolated AT II cells from our transgenic mice with targeted overexpression of CTGF in these cells and cultured them on Matrigel. This culture system has the ability to maintain certain of AT II cell behaviors such as forming alveolar-like cysts and expressing surfactant proteins (33, 40) . We showed that AT II cells with overexpression of CTGF are larger, some of them are in spindle shape and do not form alveolar-like cyst. Furthermore, these cells expressed mesenchymal markers such as α-SMA, fibronectin, and vimentin, suggesting EMT-like changes. Sonnylal et al., have demonstrated that CTGF causes EMT-like cell fate in vivo and in vitro in the lung (31, 32) . They used transgenic mice with mesenchymal overexpression of CTGF driven by the collagen 1a2 promoter as well as lung epithelial cells lines A549 and SV40-T2. The in vivo studies revealed that lung fibrosis is associated with a marked increase in cells coexpressing epithelial and mesenchymal markers suggesting EMT. In vitro, they showed that adenoviral mediated overexpression of CTGF as well as treatment with recombinant CTGF induces EMT-like changes in lung epithelial cells. Taken together, these studies provided important evidence that fibroblast-CTGF and epithelial-CTGF via autocrine and paracrine mechanisms induces lung fibrosis and EMT.
The important finding of this study is that we identified a novel signaling pathway, the CTGF-ILK pathway regulates EMT in AT II cells. ILK is an intracellular serine/threonine protein kinase that interacts with the cytoplasmic domains of integrins and numerous cytoskeleton-associated proteins. CTGF has the ability to bind to cell surface integrins, thus activating ILK signaling. ILK has been identified as a regulator of EMT in several epithelia e.g., renal, ovary, and lens and mammary glands (25) (26) (27) . We showed that AT II cells with overexpression These data indicate that overexpression of CTGF-induced EMT in AT II cells is at least in part mediated by ILK. Besides ILK, many other intracellular kinases such as focal adhesion kinase and extracellular signal-regulated kinase (ERK) also mediate integrin signaling (22) . Moreover, CTGF can also activate p42/44 mitogen-activated protein kinase (MAPK) as well as Smad2/3 signaling via integrin-independent mechanisms (14) . Previous studies have shown that overexpression of CTGF in skin and lung fibroblasts activates MAPK and ERK signaling in the adjacent epithelial cells that undergo EMT-like changes (31, 32) . It is unclear whether activation of MAPK and ERK in these cells via integrin-dependent signaling. Given the complexity of CTGF signaling network and its biological significance in lung fibrosis, further investigation is needed to delineate the role of these kinases in mediating CTGF-integrin signaling in alveolar epithelial cells that may contributes to our overall understanding in the mechanisms by which CTGF-induces EMT in lung fibrosis.
In summary, this in vitro study demonstrates that transgenic overexpression of CTGF induces EMT-like phenotype in AT II cells. Furthermore, knockdown of ILK attenuates this process, thus suggesting an autocrine mechanism by which CTGF-ILK signaling regulates EMT in AT II cells. Although there are increasing reports on the critical role of EMT in lung fibrosis in animal models and in cell cultures, little is known about the role of EMT in patients developing lung fibrosis. Much work needs to be done to elucidate the potential autocrine and paracrine mechanisms by which CTGF-ILK signaling contributes to EMT and lung fibrosis in human. This may help to generate novel therapies by targeting CTGF-ILK signaling to prevent and treat lung fibrosis, a devastating disorder that affects patients from neonates to adults.
METHODS
CTGF Transgenic Mice
The study protocols were reviewed and approved by the Animal Care and Use Committee at the University of Miami (Miami, FL). The conditional and tissue-specific overexpression of CTGF was achieved by mating two lines of transgenic mice, the SP-C-rtTA mice (line 2), bearing the reverse tetracycline responsive transactivator (rtTA) under the control of the 3.7-kb rat SP-C gene promoter and the TetO-CTGF mice, containing tetracycline operator (TetO) and minimal CMV promoter and CTGF transgene, as we have previously described (33) . The SP-C-rtTA mice were provided by Dr Jeffrey Whitsett (Cincinnati Children's Hospital, Cincinnati, OH) and the TetO-CTGF mice were generated in the University of Miami Transgenic Facility. To generate double transgenic mice, the homozygous SP-C-rtTA mice were mated with the heterozygous TetO-CTGF mice. The newborn mice were genotyped by PCR of tail DNA with SP-C-rtTA and TetO-CTGF primers as previously described (33) . The single transgenic SP-CrtTA mice were used as control mice, and the double transgenic SP-C-rtTA/Teto-CTGF mice were used and referred to as CTGF+ mice. To induce CTGF expression in the lungs of newborn pups, the nursing dams were fed with Dox containing water (1 mg/ml) from postnatal day (P) 1.
Primary AT II Cell Culture
AT II cells were isolated and cultured from 4 wk old control and CTGF+ mice as previously described with some modification (33, 40) . Mice were sacrificed by intraperitoneal injection of pentobarbital and tracheotomized. The lungs were infused with dispase solution followed by low melting agarose via a tracheal catheter and were covered by ice to allow the agarose to polymerize. The lungs were then dissected and digested in dispase and teased from the bronchi in DNase solution. The cell suspension was filtered through gradient cell strainers (100 µm to 20 µm), and the cells were pelleted by centrifugation and then placed on tissue culture plates precoated with anti-CD 45 and anti-CD 32 antibodies (BD Biosciences, San Jose, CA). After incubation for 2 h in a humidified 37 °C incubator with 21% O 2 and 5% CO 2 , the AT II cells (nonadhered) were collected, centrifuged and placed on Matrigel (70%)-coated eight-well chamber slides or six-well plates (BD Biosciences). The AT II cells were cultured overnight in bronchial epithelial cell growth medium minus hydrocortisone (Lonza, Portsmouth, NH) with 5% charcoal stripped fetal calf serum and keratinocyte growth factor. The media were changed to fresh media containing Dox (1 µg/ml) and the cells were cultured for up to 96 h. The purity of AT II cells was typically >90%, as assessed by pro-SP-C immunofluorescence staining.
Knockdown of ILK
A mix of three siRNA targeting mouse ILK (Qiagen, Valencia, CA) were used to knockdown ILK in AT II cells. These siRNA preparations (100 nmol/l of each) or all-star negative control siRNA were incubated with HiPerFect (Qiagen) and then added to the AT II cells that have been cultured overnight according to the manufacture protocol. After 24 h transfection, the cell culture media was changed to fresh bronchial epithelial cell growth medium containing 1 µg/ml of doxycycline. The transfection was repeated at 48 h to increase transfection efficiency. At 96 h, live cell morphology was imaged under a light microscope.
Analysis of Gene Expression by qRT-PCR
Total RNA was isolated from frozen lung tissues and AT II cells and treated with DNase to remove possible DNA contamination as described (34) . One µg of total RNA was reverse-transcribed in a 20 µl reaction by using a first-strand cDNA synthesis kit according to manufacturer's protocol (Invitrogen, Grand Island, NY). The Realtime RT-PCR was performed on an ABI Fast 7500 System (Applied Biosystems, Foster City, CA). Each reaction included diluted firststrand cDNA, specific primers and master mix containing enzymes and TaqMan probes according to the manufacture's instruction (Applied Biosystems). Real-time RT-PCR conditions were 95 °C for 10 min, followed by 40 cycles of 95 °C for 15 s and 60 °C for 30 s. RNase-free water was used as a negative control. For each target gene, a standard curve was established by performing a series of dilutions of the first-strand cDNA. The mRNA expression levels of target genes were determined from the standard curve and normalized to GAPDH.
Western Blot Analysis
Total protein was extracted from cells with a RIPA buffer according to manufacturer's protocol (Santa Cruz Biotechnology, Santa Cruz, CA). The protein concentrations were measured by bicinchoninic acid protein assay using a commercial kit from Pierce Biotechnology (Rockford, IL). Total proteins (50 µg/sample) were fractionated by SDS-PAGE on 4-12% Tris-glycine precast gradient gels (Invitrogen) and then transferred to nitrocellulose membranes (Amersham, Piscataway, NJ). The membranes were incubated overnight at 4 °C with respective primary antibodies and then incubated for 1 h at room temperature with horseradish peroxidase (HRP)-conjugated secondary antibodies. Antibody bound proteins were detected using enhanced chemiluminescent (ECL) chemiluminescence methodology (Amersham). Membranes were then stripped with 0.2 N NaOH and re-incubated with primary antibodies reactive with a normalization protein, β-actin. The intensities of protein bands were quantified by Quantity One Imaging Analysis Program (Bio-Rad, Hercules, CA).
Double Immunofluorescence Staining
The following primary antibodies were used in immunostaining and immunofluorescence staining: a goat anti-CTGF antibody from Santa
